July 12, 2022 7:47am

A lean and anxious market followed by a panicky sector as risk-off sentiment straddled Monday’s session

Pre-open indications:  1 Positive Indication, 2 Negative Indications and 1 Puff/Pump/Promote

NEWS: Verve Therapeutics (VERV) the first patient has been dosed with VERVE-101, in its heart-1 clinical trial. VERVE-101 is a novel, investigational gene editing medicine developed by Verve and designed to be a single-course treatment that permanently turns off the PCSK9 gene in the liver to reduce disease-driving low-density lipoprotein cholesterol (LDL-C).

RMi outlines a daily bell ringing of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

The 8:00 A.M., ET edition

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.


Dow futures are DOWN -0.63% or (-196 points), S&P futures are DOWN -0.39% (-15 points) and NASDAQ futures are UP +0.07% (+8 points) early in the pre-open – so far,


U.S. stock futures are mixed and fluctuating on Tuesday,

European stocks traded lower,

Asia pacific stocks were either flat or down.



On Monday, the Dow shed 164.31 points, or 0.5%. The S&P 500 fell -44.95 points or 1.15%, while the Nasdaq dived -262.71 or -2.26%.


RegMed Investors’ (RMi) closing bell: “this week’s expectation and economics. It’s some part about Q2 earnings but mostly about declining share pricing; hoping for catalysts (hope is also not an action initiative).” https://www.regmedinvestors.com/articles/12510

Ebb and flow –

Q3/22 – 1 holiday, 2 negative and 4 positive closes

Q2/22 –

June – 1 holiday, 9 positive and 11 negative closes

·         May - 11 positive and 10 negative closes

·         April - 1 holiday, 6 positive and 13 negative closes


·         March – 13 negative and 10 positive closes

·         February stats: 11 negative, 8 positive closes and 1 holiday

·         January stats: 2 holidays, 1 neutral, 13 negative and 6 positive closes


Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS

Positive Indication:

Chinook Therapeutics (KDNY) closed down -$0.57 to $17.94 with a positive +$0.30 or +1.67% pre-open indication.


Negative Indication:

UniQure NV (QURE) closed down -$0.61 to $22.16 after Monday’s +$0.86, Thursday’s +$1.72, Wednesday’s -$0.65 and last Tuesday’s +$1.66) with a negative -$0.67 or -3.02% pre-open indication,

CRISPR Therapeutics (CRSP) closed down -$2.99 to $73.71 with a negative -$0.71 or -0.96% pre-open indication,


Puff/Pump and Promote: Maintaining SELL

Biostage (OTCQB: BSTG) closed down -$1.189 with 5,387 shares traded after Friday’s -$0.55 to $5.70 with 2,334 shares traded, Thursday’s +$0.23 to $6.25 with 4,771 shares traded, Wednesday’s +$1.22 to $6.02 with 14, 121 shares traded <3 mo. Average = 1,703 shares> and last Tuesday’s +$0.32 to $4.80 with 496 shares traded.

·         BSTG seems to always finagling a finagle and NOTHING is CLEAN and STRAIGHTFORWARD; is it the ONLY avenue to finance to utilize non-U.S. Chinese investors?

·         How much lipstick is a lot on this pig with an almost 4-year-old IND and NO clinical trial initiation?

·         WATCH and be ready for a BIG reverse of shares to enable offering from multiple private placements as it tries to facilitate an offering with Newbridge Securities


The BOTTOM LINE: I try to keep it simple … and short!

The cell and gene therapy sector equities fell from resistance Monday on looming inflation data after a strong week (only one negative close) but is at a make-or-break point.

The Nasdaq fell back from the 50-day and 10-week moving averages. which have served as major resistance in 2022. <IBD>

I remain cautious, after a week of “love”; a sell-off at current pricing would be a serious downward signal especially as we enter the Q2 earnings cycle. A few bad days would turn recent buys into clear losses, with the sector heading toward lows once again.

However, last week's sector gains came on light volume, suggesting institutions aren't making bets -it’s just an algorithmic frenzy.

A few bad days would turn recent buys into clear losses, with the sector heading back into new lows once again.


BUILD CASH POSITIONS, the upward spiral will be STRIPPED, maybe NOT all today but, it’s coming.

Be prepared, earnings or LPS (loss-per-share) sessions are on their way and many companies will be just as glad to get them out as fast-as-possible to re-set ANY trajectory in August for September.”

There is VALUE out there however, it’s about playing or betting the timing of the sector.

We are left with choosing to hang on to “our” portfolio position as it is a given that the sector shifts from fierce, sudden sell-offs to gaining altitude or ascending not to its value but, better than it was.

Whether information or intelligence is good, bad or somewhere in between; RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.